Sarepta Therapeutics Financial Statements (SRPT)
|
|
|
|
Report date
|
|
|
01.03.2022 |
28.02.2023 |
28.02.2024 |
28.02.2025 |
02.03.2026 |
|
06.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
701.9 |
933.0 |
1 243 |
1 902 |
2 198 |
|
2 184 |
|
Operating Income, bln rub |
|
|
-459.7 |
-536.2 |
-267.8 |
218.1 |
-657.8 |
|
-41.0 |
|
EBITDA, bln rub |
? |
|
-317.4 |
-594.9 |
-453.7 |
316.9 |
-648.0 |
|
121.6 |
|
Net profit, bln rub |
? |
|
-418.8 |
-703.5 |
-536.0 |
235.2 |
-713.4 |
|
65.1 |
|
|
OCF, bln rub |
? |
|
-443.2 |
-325.3 |
-501.0 |
-205.8 |
-205.5 |
|
175.3 |
|
CAPEX, bln rub |
? |
|
38.5 |
32.3 |
87.3 |
147.0 |
102.0 |
|
68.1 |
|
FCF, bln rub |
? |
|
-481.7 |
-357.6 |
-588.3 |
-352.7 |
-307.5 |
|
107.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
1 065 |
1 329 |
1 361 |
1 365 |
1 975 |
|
1 404 |
|
Cost of production, bln rub |
|
|
97.0 |
140.0 |
150.3 |
319.1 |
881.5 |
|
821.4 |
|
R&D, bln rub |
|
|
771.2 |
877.1 |
877.4 |
804.5 |
1 522 |
|
902.6 |
|
Interest expenses, bln rub |
|
|
63.5 |
53.2 |
22.0 |
18.4 |
9.73 |
|
42.1 |
|
|
Assets, bln rub |
|
|
3 148 |
3 128 |
3 265 |
3 963 |
3 350 |
|
3 179 |
|
Net Assets, bln rub |
? |
|
928.0 |
385.0 |
859.3 |
1 528 |
1 141 |
|
1 505 |
|
Debt, bln rub |
|
|
1 153 |
1 617 |
1 397 |
1 343 |
1 040 |
|
1 037 |
|
Cash, bln rub |
|
|
2 116 |
1 989 |
1 676 |
1 355 |
939.7 |
|
653.2 |
|
Net debt, bln rub |
|
|
-962.4 |
-372.0 |
-279.4 |
-11.7 |
99.9 |
|
383.5 |
|
|
Ordinary share price, rub |
|
|
90.1 |
129.6 |
96.4 |
121.6 |
21.5 |
|
20.0 |
|
Number of ordinary shares, mln |
|
|
81.3 |
87.6 |
92.4 |
95.1 |
104.8 |
|
105.0 |
|
|
Market cap, bln rub |
|
|
7 318 |
11 346 |
8 910 |
11 560 |
2 255 |
|
2 095 |
|
EV, bln rub |
? |
|
6 355 |
10 974 |
8 630 |
11 548 |
2 355 |
|
2 479 |
|
Book value, bln rub |
|
|
914 |
377 |
830 |
1 501 |
1 112 |
|
1 474 |
|
|
EPS, rub |
? |
|
-5.15 |
-8.03 |
-5.80 |
2.47 |
-6.81 |
|
0.62 |
|
FCF/share, rub |
|
|
-5.93 |
-4.08 |
-6.37 |
-3.71 |
-2.93 |
|
1.02 |
|
BV/share, rub |
|
|
11.2 |
4.31 |
8.98 |
15.8 |
10.6 |
|
14.0 |
|
|
EBITDA margin, % |
? |
|
-45.2% |
-63.8% |
-36.5% |
16.7% |
-29.5% |
|
5.57% |
|
Net margin, % |
? |
|
-59.7% |
-75.4% |
-43.1% |
12.4% |
-32.5% |
|
2.98% |
|
FCF yield, % |
? |
|
-6.58% |
-3.15% |
-6.60% |
-3.05% |
-13.6% |
|
5.11% |
|
ROE, % |
? |
|
-45.1% |
-182.7% |
-62.4% |
15.4% |
-62.5% |
|
4.32% |
|
ROA, % |
? |
|
-13.3% |
-22.5% |
-16.4% |
5.94% |
-21.3% |
|
2.05% |
|
|
P/E |
? |
|
-17.5 |
-16.1 |
-16.6 |
49.1 |
-3.16 |
|
32.2 |
|
P/FCF |
|
|
-15.2 |
-31.7 |
-15.1 |
-32.8 |
-7.33 |
|
19.6 |
|
P/S |
? |
|
10.4 |
12.2 |
7.17 |
6.08 |
1.03 |
|
0.96 |
|
P/BV |
? |
|
8.01 |
30.1 |
10.7 |
7.70 |
2.03 |
|
1.42 |
|
EV/EBITDA |
? |
|
-20.0 |
-18.4 |
-19.0 |
36.4 |
-3.63 |
|
20.4 |
|
Debt/EBITDA |
|
|
3.03 |
0.63 |
0.62 |
-0.04 |
-0.15 |
|
3.15 |
|
|
R&D/CAPEX, % |
|
|
2 004% |
2 720% |
1 005% |
547.5% |
1 493% |
|
1 325% |
|
|
CAPEX/Revenue, % |
|
|
5.48% |
3.46% |
7.03% |
7.73% |
4.64% |
|
3.12% |
|
| Sarepta Therapeutics shareholders |
